JHS Svendgaard Laboratories Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de JHS Svendgaard Laboratories.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Personal Products	11.6%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

JHS Svendgaard Laboratories Limited (NSE:JHS) Not Doing Enough For Some Investors As Its Shares Slump 33%

Mar 07

JHS Svendgaard Laboratories Limited's (NSE:JHS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

Jan 22

A Look At The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

Aug 19

There Are Reasons To Feel Uneasy About JHS Svendgaard Laboratories' (NSE:JHS) Returns On Capital

Aug 04

JHS Svendgaard Laboratories (NSE:JHS) Will Want To Turn Around Its Return Trends

Apr 09

Estimating The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

Dec 01

Here’s What’s Happening With Returns At JHS Svendgaard Laboratories (NSE:JHS)

Jun 25

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como JHS Svendgaard Laboratories no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NSEI:JHS - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2023	874	-111	N/A	N/A	N/A
9/30/2023	939	-139	-220	-172	N/A
6/30/2023	938	-144	N/A	N/A	N/A
3/31/2023	1,026	-155	182	189	N/A
12/31/2022	899	-99	N/A	N/A	N/A
9/30/2022	854	-82	117	167	N/A
6/30/2022	860	-77	N/A	N/A	N/A
3/31/2022	872	-41	-159	-91	N/A
12/31/2021	927	29	N/A	N/A	N/A
9/30/2021	988	28	-144	-116	N/A
6/30/2021	1,056	35	N/A	N/A	N/A
3/31/2021	1,010	12	37	120	N/A
12/31/2020	1,192	-32	N/A	N/A	N/A
9/30/2020	1,290	-27	75	130	N/A
6/30/2020	1,331	-42	N/A	N/A	N/A
3/31/2020	1,416	-20	1	104	N/A
12/31/2019	1,355	-3	N/A	N/A	N/A
9/30/2019	1,382	-15	N/A	N/A	N/A
6/30/2019	1,294	-5	N/A	N/A	N/A
3/31/2019	1,269	-7	-264	-108	N/A
12/31/2018	1,274	23	N/A	N/A	N/A
9/30/2018	1,318	40	N/A	N/A	N/A
6/30/2018	1,329	67	N/A	N/A	N/A
3/31/2018	1,406	261	30	138	N/A
12/31/2017	1,304	419	N/A	N/A	N/A
9/30/2017	1,093	411	N/A	N/A	N/A
6/30/2017	1,090	407	N/A	N/A	N/A
3/31/2017	1,051	219	N/A	-39	N/A
12/31/2016	1,031	-143	N/A	N/A	N/A
9/30/2016	1,059	-175	N/A	N/A	N/A
6/30/2016	1,007	-198	N/A	N/A	N/A
3/31/2016	1,001	-216	N/A	-38	N/A
12/31/2015	959	-130	N/A	N/A	N/A
9/30/2015	835	-149	N/A	N/A	N/A
6/30/2015	696	-186	N/A	N/A	N/A
3/31/2015	553	-222	N/A	73	N/A
12/31/2014	418	-178	N/A	N/A	N/A
9/30/2014	363	-224	N/A	N/A	N/A
6/30/2014	330	-270	N/A	N/A	N/A
3/31/2014	353	-288	N/A	282	N/A
12/31/2013	468	-176	N/A	N/A	N/A
9/30/2013	506	-145	N/A	N/A	N/A
6/30/2013	550	-152	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de JHS es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de JHS crezcan más rápidamente que el mercado Indian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de JHS crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de JHS crezcan más rápidamente que el mercado de Indian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de JHS crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de JHS se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

JHS Svendgaard Laboratories Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

JHS Svendgaard Laboratories Limited Update on Its Operations

Recent updates

JHS Svendgaard Laboratories Limited (NSE:JHS) Not Doing Enough For Some Investors As Its Shares Slump 33%

Third quarter 2024 earnings released: EPS: ₹0.002 (vs ₹0.24 loss in 3Q 2023)

JHS Svendgaard Laboratories Limited to Report Nine Months, 2024 Results on Feb 14, 2024

New major risk - Share price stability

JHS Svendgaard Laboratories Limited's (NSE:JHS) Price Is Right But Growth Is Lacking After Shares Rocket 27%

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.03 loss in 2Q 2023)

JHS Svendgaard Laboratories Limited to Report First Half, 2024 Results on Nov 07, 2023

JHS Svendgaard Laboratories Limited Announces the Resignation of Mr. Deepesh Sharma as Joint Chief Financial Officer

JHS Svendgaard Laboratories Limited Announces Cessation of Rohina Sanjay Sangtani as Independent Director

New minor risk - Shareholder dilution

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 28, 2023

A Look At The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

JHS Svendgaard Laboratories Limited (NSEI:JHS) agreed to acquire Vedic Cosmeceuticals Pvt. Ltd.

First quarter 2024 earnings released: ₹0.40 loss per share (vs ₹0.59 loss in 1Q 2023)

JHS Svendgaard Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023

New minor risk - Share price stability

Full year 2023 earnings released: ₹2.34 loss per share (vs ₹0.63 loss in FY 2022)

JHS Svendgaard Laboratories Limited Appoints Deepesh Sharma as Joint Chief Financial Officer

JHS Svendgaard Laboratories Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: ₹0.24 loss per share (vs ₹0.04 profit in 3Q 2022)

JHS Svendgaard Laboratories Limited Announces the Resignation of Neeraj Kumar as Joint Chief Financial Officer, Effective March 15, 2023

JHS Svendgaard Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022)

Second quarter 2023 earnings released: ₹0.03 loss per share (vs ₹0.05 profit in 2Q 2022)

JHS Svendgaard Laboratories Limited Appoints Komal Jha as Company Secretary & Compliance Officer

JHS Svendgaard Laboratories Limited to Report Q2, 2023 Results on Nov 10, 2022

JHS Svendgaard Laboratories Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released

JHS Svendgaard Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

There Are Reasons To Feel Uneasy About JHS Svendgaard Laboratories' (NSE:JHS) Returns On Capital

Full year 2022 earnings: EPS and revenues exceed analyst expectations

JHS Svendgaard Laboratories Limited Announces Management Changes

Investor sentiment improved over the past week

JHS Svendgaard Laboratories Limited to Report Q4, 2022 Results on May 24, 2022

Investor sentiment improved over the past week

JHS Svendgaard Laboratories (NSE:JHS) Will Want To Turn Around Its Return Trends

Investor sentiment improved over the past week

JHS Svendgaard Laboratories Limited Announces Resignation of Mr. Nokhil Kishorchandra Vora as Nominee Director

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

JHS Svendgaard Laboratories Limited to Report Q3, 2022 Results on Feb 08, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.05 (vs ₹0.16 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹0.20 (vs ₹0.33 loss in FY 2020)

JHS Svendgaard Laboratories Limited Update on Its Operations

Third quarter 2021 earnings released: EPS ₹0.02 (vs ₹0.11 in 3Q 2020)

JHS Svendgaard Laboratories Limited to Report Q3, 2021 Results on Feb 09, 2021

New 90-day high: ₹26.90

New 90-day high: ₹26.60

Estimating The Fair Value Of JHS Svendgaard Laboratories Limited (NSE:JHS)

JHS Svendgaard Laboratories Limited to Report Q2, 2021 Results on Nov 03, 2020

First quarter earnings released

JHS Svendgaard Laboratories Limited Announces Resignation of Balbir Verma, Non-Executive Independent Director

JHS Svendgaard Laboratories Limited to Report Q1, 2021 Results on Sep 15, 2020

New 90-day high - ₹19.45

JHS Svendgaard Laboratories Limited announced that it expects to receive INR 27.5 million in funding

Here’s What’s Happening With Returns At JHS Svendgaard Laboratories (NSE:JHS)

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento